# Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

> **NCT00273910** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 104 (actual)

## Conditions studied

- High-Risk Melanoma

## Interventions

- **DRUG:** gp100:209-217 (210M)
- **DRUG:** Montanide ISA-51
- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT00273910
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2012-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00273910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00273910, "Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00273910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*